Your browser is no longer supported. Please, upgrade your browser.
Settings
COCP Cocrystal Pharma, Inc. daily Stock Chart
COCP [NASD]
Cocrystal Pharma, Inc.
Index- P/E- EPS (ttm)-1.57 Insider Own38.38% Shs Outstand41.66M Perf Week20.71%
Market Cap108.87M Forward P/E- EPS next Y-0.18 Insider Trans0.00% Shs Float32.23M Perf Month11.48%
Income-53.10M PEG- EPS next Q-0.04 Inst Own15.30% Short Float1.06% Perf Quarter117.62%
Sales1.90M P/S57.30 EPS this Y13.70% Inst Trans-0.04% Short Ratio0.07 Perf Half Y274.45%
Book/sh0.97 P/B2.10 EPS next Y0.00% ROA-96.70% Target Price- Perf Year-29.17%
Cash/sh0.41 P/C5.02 EPS next 5Y- ROE-101.50% 52W Range0.39 - 3.04 Perf YTD311.71%
Dividend- P/FCF- EPS past 5Y- ROI-187.60% 52W High-32.89% Beta0.11
Dividend %- Quick Ratio11.70 Sales past 5Y273.80% Gross Margin- 52W Low428.36% ATR0.29
Employees11 Current Ratio11.70 Sales Q/Q-90.20% Oper. Margin- RSI (14)56.01 Volatility27.76% 15.50%
OptionableNo Debt/Eq0.00 EPS Q/Q-148.80% Profit Margin- Rel Volume0.74 Prev Close2.08
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume4.92M Price2.04
Recom2.00 SMA204.84% SMA5030.94% SMA200113.55% Volume3,635,039 Change-1.92%
Jul-08-20Initiated H.C. Wainwright Buy $5
Aug-06-20 08:05AM  
Aug-04-20 08:05AM  
May-28-20 03:25PM  
May-15-20 06:36AM  
May-14-20 07:05AM  
May-11-20 08:05AM  
Apr-22-20 08:05AM  
Apr-20-20 08:05AM  
Apr-15-20 08:05AM  
Mar-30-20 06:05AM  
Mar-11-20 09:40AM  
Mar-10-20 10:00AM  
Mar-09-20 03:00PM  
Mar-06-20 04:01PM  
Feb-28-20 02:00PM  
Feb-27-20 07:00AM  
Feb-25-20 03:25PM  
Feb-24-20 08:00AM  
Feb-17-20 02:35PM  
Feb-13-20 08:30AM  
Feb-11-20 08:35AM  
Feb-03-20 08:05AM  
Jan-29-20 09:45AM  
Dec-18-19 05:49PM  
Dec-04-19 08:00AM  
Nov-12-19 08:35AM  
Nov-11-19 08:35AM  
Oct-31-19 09:00AM  
Oct-30-19 04:45PM  
08:05AM  
Oct-16-19 09:22AM  
Oct-08-19 09:15AM  
Oct-01-19 08:00AM  
Sep-26-19 08:05AM  
Sep-10-19 01:11PM  
Sep-03-19 08:05AM  
Aug-21-19 08:05AM  
Aug-09-19 08:05AM  
Jul-26-19 08:10AM  
Jun-19-19 06:03AM  
May-20-19 08:05AM  
May-10-19 08:35AM  
Apr-01-19 08:35AM  
Mar-11-19 08:30AM  
Jan-22-19 04:00PM  
08:00AM  
Jan-18-19 04:18PM  
Jan-07-19 08:30AM  
Jan-03-19 10:35AM  
08:48AM  
08:30AM  
Nov-30-18 08:00AM  
Nov-29-18 11:05AM  
Nov-19-18 11:40AM  
09:25AM  
08:40AM  
Nov-18-18 09:00AM  
Nov-16-18 07:30PM  
10:37AM  
09:00AM  
Nov-15-18 04:28PM  
01:37PM  
09:51AM  
Nov-14-18 09:00PM  
05:00PM  
04:04PM  
03:00PM  
09:15AM  
Nov-13-18 05:19PM  
03:09PM  
12:55PM  
11:50AM  
10:51AM  
10:06AM  
09:50AM  
Nov-12-18 07:39PM  
07:00PM  
05:25PM  
05:19PM  
08:00AM  
Nov-11-18 12:00PM  
Nov-10-18 08:28AM  
Nov-09-18 07:16PM  
Nov-08-18 05:55PM  
02:00PM  
12:11PM  
Nov-07-18 06:30PM  
04:20PM  
12:45PM  
09:34AM  
Nov-06-18 05:31PM  
04:11PM  
Nov-05-18 07:02PM  
05:30PM  
02:48PM  
01:48PM  
01:45PM  
Nov-04-18 11:00AM  
Nov-02-18 09:03PM  
02:42PM  
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.